US appeals refuses to grant a bar on Zytiga
Generics of Janssen’s Zytiga (abiraterone acetate) blockbuster could enter the US market imminently, after a US Court of Appeals refused twice in quick succession to grant the originator injunctions blocking such launches.
You may also be interested in...
The sole US patent listed against Janssen’s Zytiga abiraterone prostate-cancer treatment is invalid, the US Court of Appeals has confirmed after generics entered the market in November last year.
Two Years On The Market And Only A 7% Volume Share – J&J Numbers Reveal Infliximab Struggle For US Biosimilars
Value-wise, Johnson & Johnson’s sales of the Remicade original in the US fell by around a fifth last year with two biosimilars on the market, the originator has just reported. However, thanks in part to what it described as “increased discounts,” J&J was able to retain more than nine-tenths of the infliximab market by volume.
The AMR Industry Alliance has formalized its years-old Common Antibiotic Manufacturing Framework by publishing an antibiotic manufacturing standard, in what it terms a “groundbreaking step” in the drive for responsible manufacturing.